COVID vaccine maker Novavax erases doubts about its ability to remain in business

Novavax, the manufacturer of a COVID-19 vaccine, has dispelled uncertainties about its business continuity by rescinding a “going concern” notice.

In February last year, Novavax had raised doubts about its ability to remain in business and announced plans to slash spending as it worked to prepare for a fall vaccination campaign.

The company also said on Friday that its revenue rose to $94 million in the first quarter, from $81 million in the same period in 2023, as per latest Reuters report.
Read also: Novavax updated COVID vaccine gets Emergency Use Listing from WHO
Facebook Comments